Cancer Biology and Cancer Stem Cells

项目总结 癌症生物学和癌症干细胞(CB)计划是一个基础性和转化性的科学计划，旨在 了解癌症发生的基本机制。从这些见解中，我们渴望 通过以下具体目标改进癌症诊断和治疗：(1)了解规则和 正常干细胞和肿瘤干细胞的功能，(2)了解肿瘤的发生和发展的机制 以及(3)确定潜在的新治疗靶点。 该项目由Laura Attardi博士和Roeland Nusse博士共同领导。2019年，前癌症生物学 计划和癌症干细胞计划合并，经EAB批准成为目前的癌症 生物学和癌症干细胞计划。在当前的资助期内，方案成员作出了重大贡献 肿瘤干细胞的自我更新途径及其信号转导途径的研究进展 与癌症高度相关，包括最突出的Wnt和Hedgehog通路。他们还拥有 开创了一种新技术，atac-seq，使人们能够更根本地理解染色质的作用 并利用器官和小鼠模型系统来发现肿瘤的机制 抑制因子和进展，并发现新的治疗靶点。当前计划的53名成员 代表医学院(SOM)、人文与科学学院和工程学院的16个系。 成员由总计2560万美元的同行评议研究支持，其中包括34架R01、12架R35、6架U01和 3个T32s。同行评审的癌症研究资金包括来自NCI的700万美元，来自其他NIH的1200万美元 660万美元，来自其他同行审查的来源。该计划的成员具有很高的积极性和 他们的目标是使用基础科学方法来了解癌症的发生和发展，这是互动的 提高癌症诊断和治疗水平的最终目的。自2015年以来，CB计划的成员 出版稿件668篇。其中，16%代表方案内，31%代表方案间， 95%的多机构合作、43%和33%的论文分别发表在IF&>10和IF&>20的期刊上。这个 斯坦福癌症研究所(SCI)通过提供最先进的共享资源来增强该项目的目标， 种子赠款支持新项目、方案资金、务虚会、特别研讨会、对新教师的支持 招聘，以及翻译研究结果的临床试验基础设施。来自SCI的支持已经 还通过组织来促进计划内和计划间的协作 方案和工作组会议，并提供与更多面向临床的人接触的手段 计划以增强我们的翻译影响力。未来的计划包括进一步加强内部和内部 通过加强癌症重点工作小组的计划合作。

PROJECT SUMMARY The Cancer Biology and Cancer Stem Cells (CB) Program is a basic and translational science program that aims to understand the fundamental mechanisms underlying cancer development. From these insights, we aspire to improve cancer diagnosis and treatment through the following specific aims: (1) understand the regulation and function of normal and cancer stem cells, (2) understand the mechanisms of initiation and progression of epithelial cancers, and (3) identify potential new therapeutic targets. The program is co-led by Laura Attardi, PhD, and Roeland Nusse, PhD. In 2019, the former Cancer Biology Program and Cancer Stem Cells Program merged with the approval of the EAB to become the current Cancer Biology and Cancer Stem Cells Program. In the current funding period, program members have made substantial progress in understanding the self-renewal pathways of cancer stem cells and in elucidating signaling pathways of high cancer relevance, including most prominently the Wnt and Hedgehog pathways. They have also pioneered a new technology, ATAC-seq, that enables a more fundamental understanding of the role of chromatin in gene expression and used organoid and mouse model systems to discover the mechanisms of tumor suppressors and progression and to uncover new therapeutic targets. The 53 members of the current program represent 16 departments within the Schools of Medicine (SOM), Humanities and Sciences, and Engineering. Members are supported by peer-reviewed research totaling $25.6M, including 34 R01s, 12 R35s, 6 U01s, and 3 T32s. Peer-reviewed cancer-focused research funding consists of $7M from the NCI, $12M from other NIH sources, and $6.6M from other peer-reviewed sources. The members of this program are highly motivated and interactive in their goal to use basic science approaches to understand cancer initiation and progression, with the ultimate aim of improving cancer diagnosis and treatment. Since 2015, members of the CB Program have published 668 manuscripts. Of these, 16% represent intra-programmatic, 31% represent inter-programmatic, and 95% multi-institutional collaborations, 43% and 33% are in journals with IF>10 and IF>20, respectively. The Stanford Cancer Institute (SCI) enhances the program’s goals by providing state-of-the-art shared resources, seed grant support for new projects, programmatic funds, retreats, special seminars, support for new faculty recruitments, and clinical trial infrastructure for translation of research findings. The support from the SCI has also been instrumental in promoting both intra- and inter-programmatic collaborations through organizing programmatic and working group meetings and providing the means to interface with the more clinically oriented programs to enhance our translational impact. Future plans incluce to further enhance intra- and inter- progammtic collaborations by enhance cancer focused working groups.